Walleye Capital’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Walleye Capital’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-49,694	Closed	-$501K	–	3765
2022 Q3	$501K	Hold	49,694	–	–	0.01%	1470
2022 Q2	$500K	Hold	49,694	–	–	0.01%	1031
2022 Q1	$500K	Sell	49,694 -42	-0.1%	-$424	0.01%	1012
2021 Q4	$502K	Buy	+49,736	New	+$503K	0.02%	982

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Walleye Capital's PBAXU Position: Q4 2022 in Review

Walleye Capital sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 49,694 shares — an estimated $501K sold.

Walleye Capital first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $502K in Q4 2021. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

Walleye Capital reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Walleye Capital sold 49,694 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $501K.
Walleye Capital first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Walleye Capital's Phoenix Biotech Acquisition Corp. Unit position peaked at $502K in Q4 2021.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.